Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy

Cell Research

Volumn 17, Issue 2, 2007, Pages 89-99

  Zhang, Qi ^a   Chen, Guihua ^a   Liu, Xinyuan ^b   Qian, Qijun ^c  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Gene therapy; Monoclonal antibody

Indexed keywords

MONOCLONAL ANTIBODY;

ANIMAL; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; NEOPLASM; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; GENE THERAPY; HUMANS; NEOPLASMS;

EID: 33847143128     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/sj.cr.7310143     Document Type: Review

References (62)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of pre-defined specificity. Nature 1975; 256:495-497.
2. Chester K, Pedley B, Tolner B, et al. Engineering antibodies for clinical applications in cancer. Tumour Biol 2004; 25:91-98.
3. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 2002; 13:603-608.
4. Ross J, Gray K, Schenkein D, et al. Antibody-based therapeutics in oncology. Expert Rev Anticancer Ther 2003; 3:107-121.
5. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 2005; 54:11-29.
6. Osbourn J, Jermutus L, Duncan A. Current methods for the generation of human antibodies for the treatment of autoimmune diseases. Drug Discov Today 2003; 8:845-851.
7. Krauss J. Recombinant antibodies for the diagnosis and treatment of cancer. Mol Biotechnol 2003; 25:1-17.
8. Zangemeister-Wittke U. Antibodies for targeted cancer therapy - technical aspects and clinical perspectives. Pathobiology 2005; 72:279-286.
9. Kipriyanov SM, Le Gall F. Generation and production of engineered antibodies. Mol Biotechnol 2004; 26:39-60.
10. Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci 2002; 324:14-30.
11. Qu Z, Griffiths GL, Wegener WA, et al. Development of humanized antibodies as cancer therapeutics. Methods 2005; 36:84-95.
12. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5:292-302.
13. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353:2654-2666.
14. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and Curr Opin Immunol 2006; 18:206-213.
15. Cassard L, Cohen-Solal JF, Galinha A, et al. Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells. J Clin Invest. 2002; 110:1549-1557.
16. Mclaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:1825-1833.
17. Piro LD, White CA, Grilllo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy fro relapsed or refractory low grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10:655-661.
18. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12:177-186.
19. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17:268-276.
20. Czuczman M, Grillo-Lopez AJ, LoBuglio AI, et al. Patients with low-grade NHL treated with rituximab+CHOP experience prolonged clinical and molecular remission. ASH Annual Meeting Abstracts 2003; 102:1493.
21. Jaeger G, Neumeister P, Brezinschek R, et al. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study. Eur J Haematol 2002; 69:21-26.
22. Czuczman MS. Immunochemotherapy in indolent non-Hodgkin's lymphoma. Semin Oncol 2002; 29(Suppl 6):11-17.
23. Zinzani P. A randomized trial of fludarabine and mitoxantrone plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma. Blood 2001; 98:abstr 344.
24. Hainsworth JD, Litchy S, Burris HA III, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol. 2002; 20:4261-4267.
25. Witzig TE. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. Semin Oncol 2003; 30(Suppl 17):11-16.
26. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:2453-2463.
27. Wiseman GA, Leigh BR, Erwin WD, et al. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 2003; 18:165-178.
28. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with 131I anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329:459-465.
29. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16:3270-3278.
30. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003; 102:2351-2357.
31. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19:3244-5324.
32. Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous infusion, high-dose cytosine arabinoside. Blood 2002; 99:4343-4349.
33. Deangelo DJ, Liu D, Stone R, et al. Preliminary report of a phase 2 study of gemtuzumab ozogamicin in combination with cytarabine and daunorubicin in patients < 60 years of age with de novo acute myeloid leukemia. Proc Am Soc Clin Oncol 2003; 22:abstr 2325.
34. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92:406-413.
35. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99:3554-3561.
36. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20:3891-3897.
37. Osterborg A, Mellstedt H, Keating M. Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia. Med Oncol 2002; 19 Suppl:S21-S26.
38. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101:3413-3415.
39. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002; 20:205-213.
40. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2348.
41. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
42. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 2003; 22:abstr 3646.
43. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
44. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecanrefractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 22:abstr 1012.
45. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
46. Gatzemeier U, Rosell R, Ramlau R, et al. Cetuximab (C225) in combination with cisplatin/vinorelbine vs. cisplatin/vinorelbine alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003; 22:abstr 2582.
47. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22:1201-1208.
48. Van Cutsem E. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 2006; 11:1010-1017.
49. Wainberg Z, Hecht JR. Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opin Biol Ther 2006; 6:1229-1235.
50. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1:118-129.
51. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23:1137-1146.
52. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006; 56:226-243.
53. McCarron PA, Olwill SA, Marouf WM, Buick RJ, Walker B, Scott CJ. Antibody conjugates and therapeutic strategies. Mol Interv 2005; 5:368-380.
54. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 2005; 5:543-549.
55. Lin MZ, Teitell MA, Schiller GJ. The evolution of antibodies into versatile tumor-targeting agents. Clin Cancer Res 2005; 11:129-138.
56. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer. Science 2006; 312: 1171-1175.
57. Guo MG, Jiang MH, Yang Q, et al. Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene. Zhonghua yi xue za zhi 2004; 84:1147-1151.
58. Jiang MH, Shi WF, Zhang Q, et al. Gene therapy for Her-2 over-expression cancers using adenovirus mediated full-length anti-Her2 antibody. Clin Cancer Res 2006; 12:6179-6185.
59. Fang J, Qian JJ, Yi S, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005; 23:584-590.
60. Ghosh SS, Gopinath P, Ramesh A. Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol 2006; 133:9-29.
61. Goncalves MA, de Vries AA. Adenovirus: from foe to friend. Rev Med Virol 2006; 16:167-186.
62. Relph KL, Harrington KJ, Pandha H. Adenoviral strategies for the gene therapy of cancer. Semin Oncol 2005; 32:573-582.